HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.

AbstractPURPOSE:
To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models.
METHODS:
A total of 2,805 patients received chemotherapy for AGC in Asan Medical Center between January 2000 and December 2008 and were randomly split into training and validation sets of 1,870 and 935 patients, respectively. A prognostic model was developed from the training set.
RESULTS:
The median follow-up duration was 26.5 months (range, 10.8-116.3), during which time 2,495 patients (88.9%) died. Eight factors associated with poor prognosis were identified by multivariate analysis: ECOG performance status ≥2 (2 points), no gastrectomy, peritoneal metastasis, bone metastasis (2 points), lung metastasis, alkaline phosphatase > 120 IU/l, albumin < 3.3 g/dL, and total bilirubin > 1.2 mg/dL. A prognostic model was developed by dividing patients into good (0-1 points), moderate (2-3), and poor (≥4) risk groups. The overall survival (OS) curves for three risk groups differed significantly for both the training and the validation sets (P < 0.001 each). In the training set, the median OS for the three risk groups was 14.0, 9.4, and 5.1 months, respectively. Application of three previous prognostic models to our validation set showed that the four models, including ours, had similar ability to predict survival outcomes (c-statistics, 0.5520-0.5836).
CONCLUSION:
Validation and comparison of prognostic models indicated that our model was as effective as the previous models to stratify the patients with AGC.
AuthorsDong Hoe Koo, Baek-Yeol Ryoo, Hwa Jung Kim, Min-Hee Ryu, Sung-Sook Lee, Jung-Hwa Moon, Heung-Moon Chang, Jae-Lyun Lee, Tae Won Kim, Yoon-Koo Kang
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 68 Issue 4 Pg. 913-21 (Oct 2011) ISSN: 1432-0843 [Electronic] Germany
PMID21290247 (Publication Type: Journal Article, Validation Study)
Chemical References
  • Antineoplastic Agents
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical
  • Multivariate Analysis
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Prognosis
  • Registries
  • Risk Factors
  • Stomach Neoplasms (drug therapy, pathology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: